IL6R and head and neck cancer: Blockade of IL-6R with a humanized monoclonal antibody (Tocilizumab; TCZ) is sufficient to inhibit Bmi-1 expression and overcome the intrinsic chemoresistance of head and neck cancer stem cells (Herzog et al., 2021).